Akoya Biosciences to Partner with Acrivon Therapeutics for the Clinical Development of Acrivon’s Proprietary OncoSignature® Test into a Companion Diagnostic
June 28, 2022 08:05 ET
|
Akoya Biosciences, Inc.
The OncoSignature® test developed based on Acrivon’s AP3 platform is a first-of-its-kind spatial signature assay to identify patients most likely to respond to ACR-368, an advanced Phase 2 targeted...
Akoya Biosciences Secures CLIA Lab Certification, a Milestone for Applying Its Spatial Biology Technologies to Accelerating Precision Cancer Therapies
November 30, 2021 08:05 ET
|
Akoya Biosciences, Inc.
Certification ensures Akoya’s cutting-edge spatial biology tools meet the highest standards for translational medicine and clinical research, with longer term potential for companion diagnostics. ...